Evidence map›Paper›PMID 38227009›Full record

SynthesisPsychopharmacology2024

Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports.

Mehdi Akbari, Shiva Jamshidi, Sonay Sheikhi, Farhad Alijani, Parsa Kafshchi, David Taylor

Abstract readSystematic ReviewCase Reports
PubMed Publisher
In one paragraph

Synthesis in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Prevalence of schizophrenia spectrum and other psychotic disorders in problem gambling: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Pooled it
  2. Incidence and predictors of problem gambling in first-episode psychosis: A prospective multicentre cohort study.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mehdi AkbariDepartment of Clinical Psychology, Faculty of Psychology and Education, Kharazmi University, No.43. South Mofatteh Ave, Tehran, Iran. m.akbari@khu.ac.ir.
Shiva JamshidiDepartment of Clinical Psychology, Faculty of Psychology and Education, Kharazmi University, No.43. South Mofatteh Ave, Tehran, Iran.
Sonay SheikhiDepartment of Clinical Psychology, Faculty of Psychology and Education, Kharazmi University, No.43. South Mofatteh Ave, Tehran, Iran.
Farhad AlijaniDepartment of Clinical Psychology, Faculty of Psychology and Education, Kharazmi University, No.43. South Mofatteh Ave, Tehran, Iran.
Parsa KafshchiDepartment of Human Sciences, Faculty of Psychology, Islamic Azad University, Zanjan, Iran.
David TaylorPharmacy Department, Maudsley Hospital, Denmark Hill, London, SE5 8AF, England, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aripiprazole is an efficacious treatment for both the positive and negative symptoms of schizophrenia and is also commonly used as a mood stabilizer. It is associated with better tolerability compared with other antipsychotics. However, there are reports of patients who experience problem gambling, hypersexuality, obsessive-compulsive symptoms, and other impulsive and/or compulsive behaviors as a result of aripiprazole administration and/or dosage increase. We aimed to do a systematic review of case reports published in this regard. After screening more than 6000 titles and abstracts in ten scientific search engines, we found 35 related records comprising 59 cases. The majority of cases (n = 42, 71.18%) were male, the mean age was 33.83 years (± 13.40), and the average daily dose of aripiprazole was 11.63 mg (± 6.94). The results of our review showed that the most frequently published impulsivity adverse effect of aripiprazole is gambling, followed by hypersexuality, obsessive-compulsive symptoms/disorder, problem eating, trichotillomania, problem shopping, and kleptomania. These symptoms were experienced both by patients who had previous problems in these areas and those who did not. In the majority of cases, the symptoms appeared within 30 days after aripiprazole administration started and ceased within 30 days of its discontinuation and/or dose decrease. Clinicians should be aware of impulsivity adverse effects, monitor them, and educate both patients and the family about them.

Indexed as

Antipsychotic AgentsDisruptive, Impulse Control, and Conduct DisordersAdultAripiprazoleCompulsive BehaviorFemaleHumansImpulsive BehaviorMaleAntipsychotic AgentsAripiprazoleAdverse effectAripiprazoleCompulsiveGamblingHypersexualityImpulsiveObsessive

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.